[1]张凯秀,王雪梅,赵建民.放射性核素显像探针在细胞凋亡中的研究进展[J].国际放射医学核医学杂志,2018,(6):559-564,576.[doi:10.3760/cma.j.issn.1673-4114.2018.06.015]
　Zhang Kaixiu,Wang Xuemei,Zhao Jianmin.Research progress of radionuclide imaging probes in apoptosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):559-564,576.[doi:10.3760/cma.j.issn.1673-4114.2018.06.015]
点击复制

放射性核素显像探针在细胞凋亡中的研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第6期
页码:
559-564,576
栏目:
综述
出版日期:
2018-12-31

文章信息/Info

Title:
Research progress of radionuclide imaging probes in apoptosis
作者:
张凯秀1;  王雪梅1;  赵建民2
1. 010050 呼和浩特, 内蒙古医科大学附属医院核医学科;
2. 010050 呼和浩特, 内蒙古医科大学附属医院骨科
Author(s):
Zhang Kaixiu1;  Wang Xuemei1;  Zhao Jianmin2
1. Department of Nuclear Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China;
2. Department of Orthopedics, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China
关键词:
分子显像; 放射性同位素; 分子探针; 细胞凋亡
Keywords:
Molecular imaging; Radioisotopes; Molecular probes; Apoptosis
DOI:
10.3760/cma.j.issn.1673-4114.2018.06.015
摘要:
目前细胞凋亡的体外检测方法很多，但这些检测方法在取材、组织活检时具有创伤性，大多需要处死动物，且只能离体研究，限制了其在临床中的应用与转化。体内检测方法因可在活体内无创、实时监测凋亡，成为目前研究的热点。放射性核素凋亡细胞显像技术因具备无创、早期、动态、灵敏、定量、可在活体内检测等优势，具有良好的研究前景，是目前研究最为广泛、技术最为成熟的体内细胞凋亡检测技术。核素凋亡显像已广泛应用于心血管疾病、中枢神经系统疾病、器官移植排斥反应中的细胞凋亡检测，以及恶性肿瘤放化疗的疗效评价和预后判断等方面。笔者主要通过对放射性核素显像探针在细胞凋亡中的研究进展作一综述。
Abstract:
At present, there are many methods for detecting apoptosis in vitro, but these methods just are traumatic in material extraction and tissue biopsy by sacrificing of animals in vitro, which limits their clinical application and transformation. In vivo detection methods have become the focus of current research because of non-invasive and real-time monitoring of apoptosis in vivo. Radionuclide apoptotic cell imaging technology among has good research prospects in non-invasive, early stage, dynamic, sensitive, quantitative, and detection intravital. It is the most widely studied and mature technology for detecting apoptosis intravital. Radionuclide apoptosis imaging has been widely used in the detection of apoptosis in cardiovascular diseases, central nervous system diseases, organ transplant rejection, and the evaluation of efficacy and prognosis of malignant tumor after radiotherapy and chemotherapy. This article reviews the progress of radionuclide imaging probes in apoptosis.

参考文献/References:

[1] Wang F, Wei ZL, Sun XR, et al. Apoptosis Inducing Factor Is Involved in Stretch-Induced Apoptosis of Myoblast via a Caspase-9 Independent Pathway[J]. J Cell Biochem, 2017, 118(4):829-838. DOI:10.1002/jcb.25759.
[2] Blankenberg FG, Robbins RC, Stoot JH, et al. Radionuclide imaging of acute lung transplant rejection with annexin V[J]. Chest, 2000, 117(3):834-840. DOI:10.1378/chest.117.3.834.
[3] Jibran SM, Muhammad IG. Clinical patterns of seronegative spondyloarthropathies in a tertiary centre in Pakistan[J]. J Taibah Univ Med Sci, 2018, 13(3):298-301. DOI:10.1016/j.jtumed.2018. 03.002.
[4] 王小龙, 赵建民, 刘瑞, 等. 细胞凋亡在激素诱导性股骨头坏死中的研究进展[J]. 实用骨科杂志, 2015, 21(1):56-59. Wang XL, Zhao JM, Liu R, et al. The research development of cell apoptosis in hormone induced femoral head necrosis[J]. J Pract Orthopaedics, 2015, 21(1):56-59.
[5] 赵阳, 彭景, 张雪宁. MR分子探针与分子成像的研究进展[J]. 国际医学放射学杂志, 2015, 38(5):455-460. DOI:10.3874/j.issn.1674-1897.2015.05.Z0510. Zhao Y, Peng J, Zhang XN. Progress in magnetic molecular probes and molecular magnetic resonance imaging[J]. Int J Med Radiol, 2015, 38(5):455-460. DOI:10.3874/j.issn.1674-1897. 2015.05.Z0510.
[6] 安淑娴, 宋少莉, 黄钢. 放射性核素标记的凋亡显像剂的研究进展[J]. 国际放射医学核医学杂志, 2015, 39(6):470-477. DOI:10.3760/cma.j.issn.1673-4114.2015.06.008. An SX, Song SL, Huang G. Recent advances in apoptosis imaging using radionuclide-labeled tracers[J]. Int J Radiat Med Nucl Med, 2015, 39(6):470-477. DOI:10.3760/cma.j.issn.1673-4114. 2015. 06.008.
[7] 王健, 宋秀宇, 徐文贵, 等. 乳腺癌放射性核素分子成像研究进展[J]. 国际医学放射学杂志, 2015, 38(4):361-365. DOI:10.3874/j.issn.1674-1897.2015.04.Z0411. Wang J, Song XY, Xu WG, et al. The research progress of radionuclide molecular imaging for breast cancer[J]. Int J Med Radiol, 2015, 38(4):361-365. DOI:10.3874/j.issn.1674-1897. 2015.04.Z0411.
[8] 杨桂芬, 朱虹. 放射性核素标记Anx Ⅴ细胞凋亡分子成像在肿瘤化疗疗效评估中的价值[J]. 国际医学放射学杂志, 2013, 36(2):155-159. DOI:10.3874/j.issn.1674-1897.2013.02.Z0212. Yang GF, Zhu H. Molecular imaging of cell apoptosis with radiolabeled Anx Ⅴ in the evaluation of tumor response to chemotherapy[J]. Int J Med Radiol, 2013, 36(2):155-159. DOI:10.3874/j.issn.1674-1897.2013.02.Z0212.
[9] Pietkiewicz S, Schmidt JH, Lavrik IN. Quantification of apoptosis and necroptosis at the single cell level by a combination of imaging flow cytometry with classical Annexin V/propidium iodide staining[J]. J Immunol Methods, 2015, 423:99-103. DOI:10.1016/j.jim.2015.04.025.
[10] Head T, Dau P, Duffort S, et al. An enhanced bioluminescence-based Annexin V probe for apoptosis detection in vitro and in vivo[J/OL]. Cell Death Dis, 2017, 8(5):e2826[2018-08-12]. https://www.nature.com/articles/cddis2017141. DOI:10.1038/cddis.2017. 141.
[11] Bauwens M, De Saint-Hubert M, Devos E, et al. Site-specific 68Ga-labeled Annexin A5 as a PET imaging agent for apoptosis[J]. Nucl Med Biol, 2011, 38(3):381-392. DOI:10.1016/j.nucmedbio.2010. 09. 008.
[12] Lin MH, Wu SY, Wang HE, et al. 111In-DOTA-Annexin V for imaging of apoptosis during HSV1-tk/GCV prodrug activation gene therapy in mice with NG4TL4 sarcoma[J]. Appl Radiat Isot, 2016, 108:1-7. DOI:10.1016/j.apradiso. 2015.11.017.
[13] Vangestel C, Peeters M, Mees G, et al. In vivo imaging of apoptosis in oncology:an update[J]. Mol Imaging, 2011, 10(5):340-358. DOI:10.2310/7290.2010.00058.
[14] Schaper FL, Reutelingsperger CP. 99mTc-HYNIC-Annexin A5 in Oncology:Evaluating Efficacy of Anti-Cancer Therapies[J]. Cancers (Basel), 2013, 5(2):550-568. DOI:10.3390/cancers5020550.
[15] Zhang S, Wu Z, Li J, et al. Evaluation of the clinical relevance of anti-annexin-A5 antibodies in Chinese patients with antiphospholipid syndrome[J]. Clin Rheumatol, 2017, 36(2):407-412. DOI:10.1007/s10067-016-3510-8.
[16] Belhocine T, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent 99mTc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis[J]. Clin Cancer Res, 2002, 8(9):2766-2774.
[17] Van de Wiele C, Vermeersch H, Loose D, et al. Radiolabeled annexin-V for monitoring treatment response in oncology[J]. Cancer Biother Radiopharm, 2004,19(2):189-194. DOI:10.1089/108497804323071968.
[18] Tang C, Wang F, Hou Y, et al. Technetium-99m-labeled annexin V imaging for detecting prosthetic joint infection in a rabbit model[J]. J Biomed Res, 2015, 29(3):224-231. DOI:10.7555/JBR.29. 2013. 01.13.
[19] Schaper FL, Reutelingsperger CP. 99mTc-HYNIC-Annexin A5 in Oncology:Evaluating Efficacy of Anti-Cancer Therapies[J]. Cancers, 2013, 5(2):550-568. DOI:10.3390/cancers5020550.
[20] Hu Y, Liu G, Zhang H, et al. A Comparison of 99mTc-Duramycin and 99mTc-Annexin V in SPECT/CT Imaging Atherosclerotic Plaques[J]. Mol Imaging Biol, 2018, 20(2):249-259. DOI:10.1007/s11307-017-1111-9.
[21] Khoda Me, Utsunomiya K, Ha-Kawa S, et al. An investigation of the early detection of radiation induced apoptosis by 99mTc-Annexin V and 201thallium-chloride in a lung cancer cell line[J]. J Radiat Ras, 2012, 53(3):361-367. DOI:10.1269/jrr.11177.
[22] Taki J, Higuchi T, Kawashima A, et al. Effect of postconditioning on myocardial 99mTc-annexin-V uptake:comparison with ischemic preconditioning and caspase inhibitor treatment[J]. J Nucl Med, 2007, 48(8):1301-1307. DOI:10.2967/jnumed.106.037408.
[23] Doue T, Ohtsuki K, Ogawa K, et al. Cardioprotective effect of erythropoietin in rats subjected to ischemia-reperfusion injury:assessment of infarct size with 99mTc-AnnexinV[J]. J Nucl Med, 2008, 49(10):1694-1700. DOI:10.2967/jnumed.107.050260.
[24] Keitselaer BL, Reutelingsperger CP, Boersma HH, et al. Noninvasive detection of programmed cell loss with 99mTc-labeled Annexin A5 in heart failure[J]. J Nucl Med, 2007, 48(4):562-567.DOI:10.2967/jnumed.106.039453.
[25] Hu S, Kiesewetter DO, Zhu L, et al. Longitudinal PET imaging of doxorubicin-induced cell death with 18F-Annexin V[J]. Mol Imaging Biol, 2012, 14(6):762-770. DOI:10.1007/s11307-012-0551-5.
[26] 胡四龙. 18F-ML-10 PET/CT评价胰腺癌放化疗后细胞凋亡的实验研究[D]. 上海:复旦大学, 2013. Hu SL. 18F-ML-10 PET/CT evaluation of pancreatic cancer cell apoptosis after concurrent chemoradiation experimental research[D]. Shanghai:Fudan University, 2013.
[27] 陈顺军. 18F-ML-10 PET/CT显像探测化疗后肿瘤细胞凋亡的实验研究[D]. 郑州:郑州大学, 2017. Chen SJ. 18F-ML-10 PET/CT imaging detection experiment research of tumor cell apoptosis after chemotherapy[D]. Zhengzhou:Zhengzhou University, 2017.
[28] Liu M, Zheng S, Zhang X, et al. Cerenkov luminescence imaging on evaluation of early response to chemotherapy of drug-resistant gastric cancer[J]. Nanomedicine, 2018, 14(1):205-213. DOI:10.1016/j.nano.2017.10.001.
[29] 张毅, 郭瀛军, 王芳, 等. Annexin B1:一种新的细胞凋亡检测用蛋白[J]. 第二军医大学学报, 2003, 24(3):333-334. DOI:10.3321/j.issn:0258-879X.2003.03.031. Zhang Y, Guo YJ, Wang F, et al. Annexin B1 as a novel protein for detecting apoptosis[J]. Acad J Sec Mil Med Univ, 2003, 24(3):333-334. DOI:10.3321/j.issn:0258-879X.2003.03.031.
[30] 郑宇佳, 王明伟, 张建平, 等. 18F-SFB-Annexin B1探测化疗后肿瘤细胞凋亡的实验研究[J]. 中国癌症杂志, 2013, 23(10):798-803. DOI:10.3969/j.issn.1007-3969.2013.10.004. Zheng YJ, Wang MW, Zhang JP, et al. Experimental study on tumor response to chemotherapy with 18F-SFB-Annexin B1[J]. Chin Oncol, 2013, 23(10):798-803. DOI:10.3969/j.issn.1007-3969. 2013. 10. 004.
[31] 赵庆, 章英剑, 王芳, 等. 18F-SFB-Annexin B1探测细胞凋亡实验研究[J]. 中华核医学杂志, 2011, 31(2):112-116. DOI:10.3760/cma.j.issn.0253-9780.2011.02.010. Zhao Q, Zhang YJ, Wang F, et al. Evaluation of 18F-SFB-Annexin B1 in detecting apoptosis[J]. Chin J Nucl Med, 2011, 31(2):112-116. DOI:10.3760/cma.j.issn.0253-9780.2011.02.010.
[32] Wang MW, Wang F, Zheng YJ, et al. An in vivo molecular imaging probe 18F-Annexin B1 for apoptosis detection by PET/CT preparation and preliminary evaluation[J]. Apoptosis, 2013, 18(2):238-247. DOI:10.1007/s10495-012-0788-0.
[33] Zhao M, Zhu X, Ji S, et al. 99mTc-labeled C2A domain of synaptotagmin I as a target-specific molecular probe for noninvasive imaging of acute myocardial infarction[J]. J Nucl Med, 2006, 47(8):1367-1374.
[34] 方纬, 王峰, 季顺东, 等. 99Tcm-FM2心肌细胞凋亡显像的实验研究[J]. 中华核医学杂志, 2006, 26(3):137-140. DOI:10.3760/cma.j.issn.2095-2848.2006.03.008. Fang W, Wang F, Ji SD, et al. Experimental study of myocardial cell apoptosis with 99Tcm-FM2 imaging[J]. Chin J Nucl Med, 2006, 26(3):137-140. DOI:10.3760/cma.j.issn.2095-2848.2006.03.008.
[35] Wang F, Fang W, Zhang MR, et al. Evaluation of chemotherapy response in VX2 rabbit lung cancer with 18F-labeled C2A domain of synaptotagmin I[J]. J Nucl Med, 2011, 52(4):592-599. DOI:10.2967/jnumed.110.081588.
[36] 黄斌, 方纬, 田伟, 等. 68Ga-NOTA-Duramycin的标记与生物分布实验研究[J]. 中华核医学与分子影像杂志, 2012, 32(4):286-290. DOI:10.3760/cma.j.issn.2095-2848.2012.04.011. Huang B, Fang W, Tian W, et al.Experimental study of labeling and biodistribution of 68Ga-NOTA-Duramycin[J]. Chin J Nucl Med Mol Imaging, 2012, 32(4):286-290. DOI:10.3760/cma.j.issn.2095-2848. 2012.04.011.
[37] Hasim S, Allison DP, Mendez B, et al. Elucidating Duramycin’s Bacterial Selectivity and Mode of Action on the Bacterial Cell Envelope[J]. Front Microbiol, 2018, 9:219. DOI:10.3389/fmicb.2018.00219.
[38] Huo L,Ökesli A, Zhao M, et al. Insights into the Biosynthesis of Duramycin[J]. Appl Environ Microbiol, 2017, 83(3):e02698-16.DOI:10.1128/AEM.02698-16.
[39] Mills JC, Stone NL, Erhardt J, et al. Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation[J]. J Cell Biol, 1998,140(3):627-636. DOI:10.1083/jcb.140.3.627.
[40] Liu Z, Larsen BT, Lerman LO, et al. Detection of atherosclerotic plaques in ApoE-deficient mice using 99mTc-duramycin[J]. Nucl Med Biol, 2016, 43(8):496-505. DOI:10.1016/j.nucmedbio.2016.05.007.
[41] Wang L, Wang F, Fang W, et al. The feasibility of imaging myocardial ischemic/reperfusion injury using 99mTc-labeled duramycin in a porcine model[J]. Nucl Med Biol, 2015, 42(2):198-204. DOI:10.1016/j.nucmedbio.2014.09.002.
[42] Zhang Y, Stevenson GD, Barber C, et al. Imaging of rat cerebral ischemia-reperfusion injury using 99mTc-labeled duramycin[J]. Nucl Med Biol, 2013, 40(1):80-88. DOI:10.1016/j.nucmedbio.2012.09. 004.
[43] Montiel-Cervantes LA, Reyes-Maldonado E, Garcia-Chavez J, et al. Prognostic Value of CD95, Active Caspase-3, and Bcl-2 Expression in Adult Patients with De Novo Acute Lymphoblastic Leukemia[J]. Arch Med Res, 2018, 49(1):44-50. DOI:10.1016/j.arcmed.2018. 04. 006.
[44] Zhou D, Chu W, Rothfuss J, et al. Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis[J]. Bioorg Med Chem Lett, 2006, 16(19):5041-5046. DOI:10.1016/j.bmcl.2006.07.045.
[45] 葛青山.新型双光子纳米探针的构建及用于caspase-3活性检测研究[D]. 长沙:湖南大学, 2017. Ge QS. The construction of a new two-photon nanoprober and used in the study of caspase 3 activity detection[D]. Changsha:Hunan University, 2017.
[46] Xia CF, Chen G, Gangadharmath U, et al. In vitro and in vivo evaluation of the caspase-3 substrate-based radiotracer 18F-CP18 for PET imaging of apoptosis in tumors[J]. Mol Imaging Biol, 2013,15(6):748-757. DOI:10.1007/s11307-013-0646-7.
[47] Madar I, Ravert H, Nelkin B, et al. Characterization of membrane potential-dependent uptake of the novel PET tracer 18F-fluorobenzyltriphenyl phosphonium cation[J]. Eur J Nucl Med Mol Imaging, 2007, 34(12):2057-2065. DOI:10.1007/s00259-007-0500-8.
[48] Higuchi T, Fukushima K, Rischpler C, et al. Stable delineation of the ischemic area by the PET perfusion tracer 18F-fluorobenzyl triphenyl phosphonium after transient coronary occlusion[J]. J Nucl Med, 2011, 52(6):965-969. DOI:10.2967/jnumed.110.085993.
[49] 王腾腾, 张锦明, 张涛, 等. PET小分子凋亡显像示踪剂的研究进展[J]. 解放军医学院学报, 2015, 36(6):637-639. DOI:10.3969/j.issn.2095-5227.2015.06.032. Wang TT, Zhang JM, Zhang T,et al. Advances in small molecule radiotracer for PET imaging apoptosis[J]. Acad Chin PLA Med Sch, 2015, 36(6):637-639. DOI:10.3969/j.issn.2095-5227. 2015.06.032.
[50] Oborski MJ, Laymon CM, Lieberman FS, et al. First use of 18F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy[J]. Brain Behav, 2014, 4(2):312-315. DOI:10.1002/brb3.217.

相似文献/References:

[1]拓飞,张庆,张京,等.2014年度全国放射性核素γ能谱分析质量控制比对[J].国际放射医学核医学杂志,2015,39(5):401.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 011]
　tuo fei,zhang qing,zhang jing,et al.nationwide intercomparison for radionuclide analyses through γ-spectrometry method in 2014[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):401.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 011]
[2]汪文霞,兰晓莉,张永学.HER2的表达及其分子影像的研究进展[J].国际放射医学核医学杂志,2016,40(5):363.[doi:10.3760/cma.j.issn.1673-4114.2016.05.007]
　Wang Wenxia,Lan Xiaoli,Zhang Yongxue.Research and development of HER2 expression molecular imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):363.[doi:10.3760/cma.j.issn.1673-4114.2016.05.007]
[3]李帅,李剑明.动脉粥样硬化易损斑块放射性核素标记分子探针的研究进展[J].国际放射医学核医学杂志,2015,39(1):80.[doi:10.3760/cma.j.issn.1673-4114.2015.01.017]
　Li Shuai,Li Jianming.Research progress of molecular probes labeled with radionuclide for imaging of atherosclerosis vulnerable plaque[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):80.[doi:10.3760/cma.j.issn.1673-4114.2015.01.017]
[4]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
　Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[5]段钰,李斌,高卉,等.神经内分泌肿瘤PET/CT的应用现状与进展[J].国际放射医学核医学杂志,2013,37(3):186.[doi:10.3760/cma.j.issn.1673-4114.2013.03.014]
　DUAN Yu,LI Bin,GAO Hui,et al.Application status and progress of PET/CT in neuroendocrine tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):186.[doi:10.3760/cma.j.issn.1673-4114.2013.03.014]
[6]彭武和,程静,曹庆东.核素肺通气/灌注显像在肺栓塞诊断中的现状及进展[J].国际放射医学核医学杂志,2012,36(2):80.[doi:10.3760/cma.j.issn.1673-4114.2012.02.005]
　PENG Wu-he,CHENG Jing,CAO Qing-dong.Present situation and development of the nuclide lung ventilation/perfusion imaging in diagnosis of lung embolim[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):80.[doi:10.3760/cma.j.issn.1673-4114.2012.02.005]
[7]陈红红,白光.《人体体表放射性核素污染处理规范》解读[J].国际放射医学核医学杂志,2012,36(4):200.[doi:10.3760/cma.j.issn.1673-4114.2012.04.001]
　CHEN Hong-hong,BAI Guang.Explanation of Specifwation of Decontamination for Radionuclides Contaminated Human Wound and Skin[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):200.[doi:10.3760/cma.j.issn.1673-4114.2012.04.001]
[8]刘庆芬,武权,樊体强,等.《放射性核素摄入量及内照射剂量估算规范》解读[J].国际放射医学核医学杂志,2012,36(4):214.[doi:10.3760/cma.j.issn.1673-4114.2012.04.005]
　LIU Qing-fen,WU Quan,FAN Ti-qiang,et al.Explanation of Specification for Assessments of Intakes and Internal Doses of Radionuclides[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):214.[doi:10.3760/cma.j.issn.1673-4114.2012.04.005]
[9]张富海,孟召伟,谭建.肺癌的放射性核素分子靶向治疗[J].国际放射医学核医学杂志,2012,36(3):145.[doi:10.3760/cma.j.issn.1673-4114.2012.03.005]
　ZHANG Fu-hai,MENG Zhao-wei,TAN Jian.Radionuclide molecular target therapy for lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):145.[doi:10.3760/cma.j.issn.1673-4114.2012.03.005]
[10]陈贵兵,欧阳忠,韩成坤,等.99Tcm-3PRGD2整合素受体显像在乳腺癌定性诊断中的价值及与钼靶检查的对比研究[J].国际放射医学核医学杂志,2017,41(1):1.[doi:10.3760/cma.j.issn.1673-4114.2017.01.001]
　Chen Guibing,Ouyang Zhong,Han Chengkun,et al.Evaluation of 99Tcm-3PRGD2 integrin receptor imaging in qualitative diagnosis of breast cancer and its comparison with mammography[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(6):1.[doi:10.3760/cma.j.issn.1673-4114.2017.01.001]

备注/Memo

备注/Memo:
收稿日期:2018-08-13。
基金项目:国家自然科学基金（81360224）
通讯作者:赵建民,Email:nmzjmin@163.com
更新日期/Last Update: 2018-12-31